Drugs Made In America Acquisition (DMAA) stock price is $10.91, up 0.09% on the day, as of Nov 13, 2026. It has a market cap of $336.16Mn and a P/E ratio of 55.16, and is classified in the Alternative Asset Managers industry (Financial Services sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap336.16 Mn
P/E55.16
FCF (Yr)-539,187.00
ROA (Yr)4.94
EV to EBIT-127.64
Net Income (Yr)5.94 Mn
Enterprise Value336.12 Mn
Add ratio to table…
About
Drugs Made In America Acquisition Corp is a blank check company incorporated in the Cayman Islands as an exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company has neither engaged in any operations nor generated any revenue to date. Based on its business activities, it is considered a shell company under the…
Drugs Made In America Acquisition Corp is a blank check company incorporated in the Cayman Islands as an exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company has neither engaged in any operations nor generated any revenue to date. Based on its business activities, it is considered a shell company under the Securities Exchange Act of 1934 because it has no operations and nominal assets consisting almost entirely of cash.
The company generates no revenue as it has not commenced operations. Its primary source of funds comes from proceeds raised through its initial public offering and private placements, which are held in a trust account for the purpose of financing a future business combination. The company does not sell products or services and has no customer base for revenue generation.
The company operates through the following segments: no_segments_reported
As a blank check company seeking to effect an initial business combination, Drugs Made In America Acquisition Corp operates in a highly competitive landscape populated by numerous other special purpose acquisition companies, private equity firms, and strategic investors targeting similar acquisition opportunities. The company does not have an established industry position due to its lack of operations and reliance on a future business combination to define its operational focus.
The company serves no customers as it has not engaged in any business operations. Its activities are limited to seeking a target for an initial business combination, and it does not provide products or services to any customer base prior to such a transaction.
Sector:Financial ServicesSector rationaleThe company is a blank check company (SPAC) that exists solely to raise capital through an IPO and private placements to fund a future acquisition. Its only current activity is the management of a trust account for investment purposes, which falls under the financial services model of capital raising and asset management.Industry:Alternative Asset ManagersAlternative Asset ManagersPrimaryThe company is a blank check company (SPAC) whose sole purpose is to raise capital to effect a merger or asset acquisition. This activity of pooling capital to acquire and invest in private businesses aligns most closely with the strategies of alternative asset managers and private equity firms described in F-11.Classified using BQ-MICSCIK: 0002028614
Peer percentiles
How Drugs Made In America Acquisition ranks
Ranked against the 340 companies in Asset and Wealth Management·58 metrics · as of Nov 14, 2026
Valuation
12 metrics · Lower multiples rank higher; a negative multiple ranks last